
Intersect ENT registers $80M IPO for sinus implants
June 24, 2014 by Arezu Sarvestani

The Medical Device Business Journal — Medical Device News & Articles | MassDevice
The Defense Dept. handed out some $66.7 million in supply contracts to 5 medical device makers, covering Pap test kits, radiology and patient monitoring systems.
HeartWare International (NSDQ:HTWR) completed enrollment in a 450-patient pivotal trial considering its ventricular assist system as a destination therapy for patients with advanced heart failure.
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Boston Scientific (NYSE:BSX) employees could see their annual bonus payments shrink or grow based on the device maker’s adjusted earnings per share and global sales by the end of the year, thanks to a new performance incentive plan for 2012.
The Natick, Mass.-based med-tech titan reconfigured its employee reward system, tying the total potential payout for all regions and division into a single pool, the value of which fluctuates along with the company’s performance in 2012.
Angeion Corp. (NSDQ:ANGN) narrowed its 1st-quarter losses despite flat sales for the 3 months ended Jan. 31.
Although dragged down by a tough European climate, focusing on group purchasing organization and service revenues kept the company’s sales from sliding, the cardiorespiratory diagnostic systems maker said.
Conceptus (NSDQ:CPTS) swapped out $50 million worth of 2.25% senior notes due 2027 from a select group of holders, exchanging them for 5% notes due 2031, regulatory filings show.
The principal amount on the new notes was an even swap for the originals, which was determined in individual negotiations between Conceptus and the holders.
Zimmer Holdings (NYSE:ZMH) shares are down this morning in early trading after the orthopedics giant lowered its sales and earnings guidance for 2011 – despite beating analysts’ expectations with its third-quarter earnings.
Warsaw, Ind.-based Zimmer said third-quarter profits were $192 million, or $1.01 per share, on sales of $1.03 billion for the three months ended Sept. 30, up 5.2 percent and 6.9 percent, respectively, compared with the same period last year.
The FDA approved a surgical gel designed to temporarily stop blood flow during procedures.
The water-soluble, low-viscosity gel designed by Woburn, Mass.-based Pluromed forms a plug at body temperature to temporarily stent blood vessels without damaging them.